<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931238</url>
  </required_header>
  <id_info>
    <org_study_id>Peking JS016</org_study_id>
    <nct_id>NCT04931238</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)</brief_title>
  <official_title>Efficacy and Safety of a Recombinant Neutralizing Human Anti-SARS-CoV-2 Monoclonal Antibody JS016 in Chinese Hospitalized Patients With SARS-CoV-2 Infection (COVID-19): a Multicenter, Randomized, Open-label, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The human monoclonal antibody CB6 showed potent neutralization activity in vitro against&#xD;
      SARS-CoV-2. CB6-LALA (also called JS016) has been developed for clinical use. Phase I trials&#xD;
      among healthy volunteers has demonstrated a tolerable and safe drug profile of JS016. We aim&#xD;
      to evaluate the efficacy and safety of JS016 in patients hospitalized with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the COVID-19 pandemic is emerging as a global healthcare crisis, scientists worldwide are&#xD;
      actively developing prophylactic and therapeutic interventions. Neutralizing antibody&#xD;
      therapies are being developed for the treatment of COVID-19. The human monoclonal antibody&#xD;
      CB6 showed potent neutralization activity in vitro against SARS-CoV-2. The LALA mutation was&#xD;
      introduced to the Fc portion of CB6 (CB6-LALA) to lower the risk of Fc-mediated acute lung&#xD;
      injury in animals. CB6-LALA (also called JS016) has been developed for clinical use. Phase I&#xD;
      trials among healthy volunteers has demonstrated a tolerable and safe drug profile of JS016.&#xD;
      We aim to evaluate the efficacy and safety of JS016 in patients hospitalized with COVID-19.&#xD;
      The data from this study will inform decisions of the clinical use of JS016.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status at 28 days</measure>
    <time_frame>At 28 days from inclusion</time_frame>
    <description>Clinical status at 28 days assessed using a six level ordinal scaleï¼Œin this scale, 1 is the minimum score and presenting a better outcome as discharge, 2 means still in-hospital but no need of oxygen therapy, 3 presents in-hospital and needing of oxygen therapy, 4 presents in-hospital needing high flow nasal oxygen therapy or non-invasive mechanical ventilation, 5 presents in-hospital needing invasive mechanical ventilation or ECMO, 6 presents death and is the worse outcome as well.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality ascertained from data analysed to day 28</measure>
    <time_frame>At 28 days from inclusion</time_frame>
    <description>All cause mortality ascertained from data analysed to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days within 28 days</measure>
    <time_frame>At 28 days from inclusion</time_frame>
    <description>Ventilator-free days within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative conversion rate of SARS-CoV-2 nucleic acid in on days 14 after randomization</measure>
    <time_frame>At 14 days from inclusion</time_frame>
    <description>Negative conversion rate of SARS-CoV-2 nucleic acid in on days 14 after</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average length of hospital stay</measure>
    <time_frame>At 28 days from inclusion</time_frame>
    <description>Average length of hospital stay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence Treatment-Emergent Adverse Events of JS016</measure>
    <time_frame>Everyday after inclusion up to 28 days from inclusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events of JS016 includes the incidence of allergic reaction, secondary infection, liver dysfunction, acute kidney injury.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>JS016 treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy + JS016 injection Standard therapy including vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy Standard therapy includes vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS016</intervention_name>
    <description>Single Intravenous Injection of JS016 with a dose of 50mg/kg</description>
    <arm_group_label>JS016 treatment group</arm_group_label>
    <other_name>CB6-LALA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) infection&#xD;
&#xD;
          -  Within 7 days from the onset of clinical symptoms or 4 days from the onset of severe&#xD;
             symptoms&#xD;
&#xD;
          -  Consistent with the National Health Committee New Coronavirus pneumonia diagnosis and&#xD;
             treatment plan (Eighth Edition), general or heavy diagnostic criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sever Covid-19 Infection patients&#xD;
&#xD;
          -  SARS-Cov-2 specific antibodies (including IgM and IgG) were positive before included&#xD;
&#xD;
          -  Cardiac function grade III or IV, or left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          -  History of known or suspected active pulmonary tuberculosis or extra-pulmonary&#xD;
             tuberculosis&#xD;
&#xD;
          -  Chronic renal failure needs maintenance dialysis&#xD;
&#xD;
          -  History of solid malignant/tumor or hematological malignancy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin DU, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin DU, Prof.</last_name>
    <phone>+86 13601366216</phone>
    <email>dubin98@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Weng, Prof.</last_name>
    <phone>+86 18600017819</phone>
    <email>wengli@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Li Weng</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Weng, professor</last_name>
      <phone>15601348897</phone>
      <email>wengli@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bin Du, professor</last_name>
      <phone>+8618600017819</phone>
      <email>dubin98@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shi Jiazhuang People's Hospital</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>He Bei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinying Cao, Prof.</last_name>
      <phone>+86 13363882361</phone>
      <email>sjzcqy@126.com</email>
    </contact>
    <investigator>
      <last_name>Ling Cui, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Hei Longjiang</state>
        <zip>0451</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijiang Yu, MD</last_name>
      <phone>010-13303608899</phone>
      <email>kaijiangyu002@163.com</email>
    </contact>
    <investigator>
      <last_name>Kaijiang Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suihua first hospital</name>
      <address>
        <city>Suihua</city>
        <state>Hei Longjiang</state>
        <zip>0455</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinyang Zhang, Prof.</last_name>
      <phone>+86 13804867215</phone>
      <email>xinshuang_1986@126.com</email>
    </contact>
    <investigator>
      <last_name>Xibin Wang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020 Jul;3(3):205-212. doi: 10.1093/abt/tbaa020. Epub 2020 Aug 19. Review.</citation>
    <PMID>33215063</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>JS016</keyword>
  <keyword>spike (S) protein</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

